Gilead's Cayston Picks Up Panel Endorsement, But Not Based On Data

It was the orphan setting and urgent need for new therapies to treat the respiratory and pulmonary symptoms of cystic fibrosis that led FDA's Anti-Infective Drugs Advisory Committee to support approval of Gilead's Cayston (aztreonam lysine)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet